Monoclonal antibodies (mAb) that block P2X7 activation provide an alternate approach to prevent GVHD, but the use of such mAbs are limited to a single study of P2X7 in a mouse model of colitis, which used an anti-mouse (m) P2X7 mAb [23]. This evidence concerns the gene P2RX7 and colitis.